Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.
ISOLYTE M in Dextrose 5% is a crystalloid solution that provides water, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. The electrolytes (sodium, potassium, magnesium, chloride, acetate, and gluconate) maintain or restore intravascular volume and acid-base balance. Acetate and gluconate are bicarbonate precursors, metabolized in the liver and peripheral tissues to generate bicarbonate, thus correcting metabolic acidosis.
Source of electrolytes, calories, and water for hydration in patients with or without carbohydrate deficiency,Maintenance and replacement of fluid and electrolyte losses in pediatric patients,Treatment of hypophosphatemia,Off-label: Total parenteral nutrition component
FDA-approved: Maintenance and replacement of water, electrolytes, and calories in patients who cannot maintain adequate oral intake.,Off-label: Treatment of hypovolemia, correction of metabolic acidosis, and as a vehicle for intravenous drug delivery.
Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.
Intravenous infusion; dose determined by fluid and electrolyte requirements; typical adult rate 100-200 m L/hour.
Dextrose has a half-life of approximately 1.5–3 hours in patients with normal glucose metabolism; in renal failure, electrolyte half-lives may be prolonged. The half-life of sodium is about 2–4 hours, and potassium 2–6 hours, depending on renal function.
No true terminal half-life; infused components (water and electrolytes) follow endogenous kinetics. Dextrose half-life approx. 1-2 hours, electrolytes distribute and are excreted based on renal function.
Dextrose is metabolized via glycolysis to pyruvate then enters the TCA cycle. Acetate is metabolized via TCA cycle to bicarbonate. Phosphate is excreted renally or incorporated into ATP and other compounds.
Dextrose undergoes glycolysis and the Krebs cycle to produce ATP, carbon dioxide, and water. Acetate is metabolized in the liver and peripheral tissues to form acetyl-Co A, which enters the Krebs cycle, generating bicarbonate. Gluconate is metabolized via the pentose phosphate pathway to produce ribulose-5-phosphate and eventually bicarbonate.
Electrolytes are primarily excreted via renal pathways; dextrose is metabolized to CO2 and water, with negligible renal excretion. Specifically, sodium, potassium, magnesium, chloride, acetate, and gluconate are eliminated by the kidneys, with over 90% of infused electrolytes excreted renally.
Primarily renal; >90% of infused water and electrolytes are excreted unchanged via kidneys with minimal biliary or fecal elimination.
Sodium, potassium, chloride, magnesium, and acetate have negligible protein binding (<5%); calcium is ~45% bound to albumin; gluconate binding is minimal.
Negligible for water and electrolytes; dextrose not bound. Total protein binding <5%.
Electrolytes distribute into total body water, approximately 0.6 L/kg for adults; dextrose distributes into extracellular fluid (~0.2 L/kg) but is rapidly taken up by cells.
Sodium distributes primarily in extracellular fluid (Vd ~0.2 L/kg); water distributes in total body water (Vd ~0.6 L/kg). Dextrose distributes in extracellular and intracellular fluid with Vd ~0.2 L/kg initial.
Intravenous: 100% bioavailability.
Intravenous: 100% bioavailability for all components; not administered by other routes.
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of hyperkalemia and fluid overload; for GFR 30-50 m L/min, use with caution and monitor potassium and fluid status.
Use with caution; monitor serum potassium and adjust infusion rate based on renal function; no specific GFR-based dose reduction defined.
No specific dose adjustment for Child-Pugh class; use with caution in severe hepatic impairment due to risk of fluid overload and electrolyte imbalances.
No specific adjustment required; monitor electrolytes in severe hepatic impairment.
Intravenous infusion at a rate of 100-150 m L/kg/day for maintenance, adjusted based on weight, clinical condition, and electrolyte requirements.
Intravenous infusion; dose individualized based on weight and clinical status; typical rate 5-10 m L/kg/hour.
Use with caution due to decreased renal function; start at lower infusion rates (e.g., 0.5-1 L per 24 hours) and monitor fluid and electrolyte status closely.
Use with caution due to possible renal impairment; monitor fluid and electrolyte status; adjust rate to avoid volume overload.
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with known hypersensitivity to any component. Do not administer simultaneously with blood products through the same set due to risk of hemolysis.
None
Risk of fluid overload, electrolyte disturbances, and hyperglycemia in patients with impaired renal function, cardiac failure, or diabetes,Use with caution in patients with severe hepatic disease (risk of lactic acidosis from acetate),Monitoring of serum electrolytes, glucose, fluid balance, and acid-base status is required,Avoid extravasation: risk of tissue necrosis
Use with caution in patients with renal impairment, heart failure, or conditions causing fluid overload.,Monitor serum electrolytes, blood glucose, and fluid balance.,Risk of hyperglycemia, hyperosmolarity, and dilutional hyponatremia.,Do not administer simultaneously with blood products through the same IV line due to risk of hemolysis.,Avoid rapid infusion to prevent metabolic acidosis from lactate accumulation (acetate may cause alkalosis if excessive).
Hyperkalemia, hypernatremia, hyperphosphatemia, hypocalcemia,Severe metabolic alkalosis or lactic acidosis,Anuria or severe oliguria,Addison's disease (risk of hyperkalemia),Known hypersensitivity to any component
Absolute: Hypersensitivity to any component, hypernatremia, hyperkalemia, hypermagnesemia, hyperchloremia, or severe metabolic alkalosis.,Relative: Severe renal impairment, oliguria, or conditions with risk of fluid overload (e.g., congestive heart failure, pulmonary edema).
No specific food interactions. Patients should maintain a balanced diet as tolerated, but sodium and potassium intake may need monitoring or adjustment based on electrolyte status. Avoid excessive ingestion of high-sodium or high-potassium foods unless directed by clinician.
No specific food interactions. However, patients should maintain a balanced diet as per their medical condition. Avoid excessive intake of potassium-rich foods if at risk of hyperkalemia.
Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential ions and do not pose fetal risk when administered appropriately. Hyperglycemia from excessive dextrose may be associated with fetal macrosomia, neonatal hypoglycemia, and other metabolic disturbances, particularly in diabetic pregnancies. No specific trimester risks are identified for isotonic balanced solutions.
Isolyte M in Dextrose 5% is an intravenous electrolyte and caloric solution. At therapeutic doses, no teratogenic risk has been identified in animal studies; however, human data are limited. Inadvertent administration of large volumes leading to hyperglycemia or electrolyte imbalances (e.g., hyponatremia) could pose risks to the fetus. Use only when clearly needed and monitor maternal glucose and electrolytes closely.
Dextrose and electrolytes are normal constituents of breast milk. Infusion of ISOLYTE H with 5% dextrose does not alter milk composition or supply significantly. No adverse effects on breastfed infants are anticipated. The M/P ratio is not applicable as these are endogenous substances; no accumulation expected.
Dextrose and electrolytes are normal constituents of breast milk and are not expected to cause adverse effects in the breastfed infant at recommended doses. The M/P ratio is not applicable as components are endogenous. Use caution with high volumes or maternal glucose intolerance, but generally considered compatible with breastfeeding.
No specific dose adjustments for pregnancy; however, avoid excessive dextrose administration to prevent maternal hyperglycemia and fetal metabolic complications. Use with caution in gestational diabetes or preeclampsia; consider lower dextrose concentrations or rate adjustments based on maternal blood glucose and electrolyte levels.
Pregnancy may increase fluid requirements and alter electrolyte balance due to expanded plasma volume, increased glomerular filtration, and hormonal changes. No specific dose adjustments are established; doses should be individualized based on maternal clinical status, electrolyte levels, and glucose tolerance. Monitor for hyperglycemia due to decreased insulin sensitivity.
ISOLYTE H with Dextrose 5% is a hypertonic solution (approx. 480 m Osm/L) used for fluid and electrolyte replacement in patients with hypochloremic metabolic alkalosis and fluid losses. It should be administered through a central line due to its high osmolarity. Monitor serum electrolytes, glucose, and acid-base status. Do not administer if solution is discolored or contains particulate matter.
Check serum potassium, magnesium, and phosphate levels before infusion; monitor serum glucose closely due to dextrose content. Adjust infusion rate based on volume status and renal function. Use with caution in patients with renal impairment or hyperkalemia. Ensure compatibility with co-administered IV medications.
This IV solution provides fluids, electrolytes, and calories to help correct imbalances caused by illness or surgery.,Tell your healthcare provider if you have a history of heart failure, kidney disease, or diabetes, as this solution may affect these conditions.,You may experience discomfort at the IV site; report any pain, redness, or swelling immediately.,Regular blood tests will be needed to monitor your electrolyte levels and kidney function.,Do not stop or adjust the infusion rate on your own.
This solution provides fluids, electrolytes, and calories to maintain hydration and electrolyte balance.,Report any signs of fluid overload (e.g., shortness of breath, swelling) or allergic reactions (e.g., rash, itching).,Inform your healthcare provider if you have kidney problems, diabetes, or are on a salt-restricted diet.,The infusion may cause changes in blood sugar levels; monitoring may be required if you have diabetes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.. ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by ISOLYTE M in Dextrose 5% is a crystalloid solution that provides water, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. The electrolytes (sodium, potassium, magnesium, chloride, acetate, and gluconate) maintain or restore intravascular volume and acid-base balance. Acetate and gluconate are bicarbonate precursors, metabolized in the liver and peripheral tissues to generate bicarbonate, thus correcting metabolic acidosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Intravenous Electrolyte Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.. The standard adult dose of ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose determined by fluid and electrolyte requirements; typical adult rate 100-200 m L/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential i. ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Isolyte M in Dextrose 5% is an intravenous electrolyte and caloric solution. At therapeutic doses, no teratogenic risk has been identified in animal studies; however, human data ar. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.